 | | |
 | |||||||||||||||||||||||||||||||||
|  | ||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||
Scottish Medicines Consortium approves Pradaxa The Scottish Medicines Consortium (SMC) has accepted PradaxaŽ (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery. The European Commission granted marketing authorisation for PradaxaŽ in all 27 EU member states in March 2008. AntiCoagulation Europe regularly makes submissions to the Scottish Medicines Consortium (SMC) and to The National Institute of Clinical Excellence (NICE) and we welcome the favourable and positive decision by the SMC. | |||||||||||||||||||||||||||||||||
| | | | | | | | ||||||||||||||||||||||||||
 | ||||||||
| ||||||||
| | | | | | |||
